Related Experiment Video
Updated: Jun 22, 2026

Bladder Smooth Muscle Strip Contractility as a Method to Evaluate Lower Urinary Tract Pharmacology
Published on: August 18, 2014
Novel and potent small-molecule urotensin II receptor agonists
Fredrik Lehmann1, Erika A Currier, Bryan Clemons
1Department of Chemistry, Medicinal Chemistry, University of Gothenburg, Göteborg, Sweden.
Abstract:
A series of analogs of the non-peptidic urotensin II receptor agonist N-[1-(4-chlorophenyl)-3-(dimethylamino)propyl]-4-phenylbenzamide (FL104) has been synthesized and evaluated pharmacologically. The enantiomers of the two most potent racemic analogues were obtained from the corresponding diastereomeric mandelic amides. In agreement with previously observed SAR, most of the agonist potency resided in the (S) enantiomers. The most potent UII receptor agonist in the new series was (S)-N-[3-dimethylamino-1-(2-naphthyl)propyl]-4-(4-chlorophenyl)benzamide (EC(50)=23 nM at the urotensin II receptor).
Related Concept Videos
Antihypertensive Drugs: Angiotensin II Receptor Blockers
Transducer Mechanism: Enzyme-Linked Receptors
Major types that are helpful drug targets include:
Adrenergic Agonists: Direct-Acting Agents
These agents can be classified...
Drug-Receptor Interaction: Agonist
Agonists can bind to receptors in different ways. Some agonists bind directly to the receptor's active site, mimicking the endogenous ligand's action.
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
Antihypertensive Drugs: Direct Renin Inhibitors

